Stock listing

NASDAQ:GRCE Grace Therapeutics, Inc. Stock

Home listing (NASDAQ) of Grace Therapeutics, Inc.

Follow Grace Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:GRCE

$1.71 USD -0.02 (-1.2%)

Close on Nov 20, 2026

Past year -45.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.68 – $1.82 USDNov 20, 2026
Volume
153,907 sharesNov 20, 2026
Market cap
$35.97M USDAt the close on Nov 20, 2026 · price × 21.04M shares outstanding
52-week range
$1.64 – $5.18 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$238,253 USDMedian day 85,938 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Grace Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:GRCE · Home$1.71 USD-0.02 (-1.2%)153,907$1.71$1.82$1.68$1.73Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GRCE · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.71-0.02-1.2%$1.71$1.82$1.68153,907
$1.73+0.01+0.6%$1.73$1.76$1.7027,707
$1.72-0.03-1.7%$1.75$1.765$1.64189,071
$1.75-0.06-3.3%$1.83$1.83$1.7349,395
$1.810.000.0%$1.82$1.83$1.8113,558
$1.81-0.045-2.4%$1.84$1.875$1.8074,170
$1.855-0.005-0.3%$1.86$1.90$1.818,840
$1.86-0.005-0.3%$1.84$1.92$1.8427,961
$1.865+0.015+0.8%$1.90$1.935$1.86128,611
$1.85+0.07+3.9%$1.85$1.90$1.79114,878
$1.78-0.03-1.7%$1.81$1.90$1.7597,130
$1.81-0.03-1.6%$1.849$1.96$1.7864,540
$1.84+0.03+1.7%$1.80$2.01$1.70231,094
$1.81-0.13-6.7%$1.93$1.95$1.7699,539
$1.940.000.0%$1.95$1.98$1.8785,938
$1.94-0.07-3.5%$1.99$2.048$1.88275,709
$2.01+0.14+7.5%$1.87$2.01$1.87164,507
$1.87+0.06+3.3%$1.80$1.90$1.80110,459
$1.81-0.12-6.2%$1.97$1.99$1.67468,914
$1.93+0.015+0.8%$1.91$1.95$1.8847,222
$1.915-0.055-2.8%$1.91$1.93$1.8797,096
$1.97-0.01-0.5%$1.96$2.02$1.9477,141
$1.98+0.10+5.3%$1.90$2.07$1.8994,407
$1.88-0.01-0.5%$1.89$1.97$1.82290,431
$1.89-0.06-3.1%$1.97$2.03$1.85168,700
$1.95+0.06+3.2%$1.91$1.97$1.89109,300
$1.89-0.10-5.0%$1.97$2.01$1.85177,900
$1.99-0.03-1.5%$2.00$2.02$1.9752,400
$2.02-0.06-2.9%$2.02$2.06$1.9849,600
$2.08+0.04+2.0%$2.05$2.09$2.0337,800
$2.04-0.06-2.9%$2.05$2.07$2.0052,600
$2.10+0.03+1.4%$2.06$2.12$2.0584,300
$2.07+0.01+0.5%$2.08$2.14$2.05110,300
$2.06-0.01-0.5%$2.04$2.08$2.0179,000
$2.07+0.03+1.5%$2.04$2.07$2.00105,000
$2.04-0.11-5.1%$2.11$2.13$1.98344,200
$2.15+0.04+1.9%$2.14$2.16$2.1025,300
$2.11-0.01-0.5%$2.11$2.15$2.09130,200
$2.120.000.0%$2.12$2.14$2.0958,700
$2.12-0.04-1.9%$2.14$2.14$2.1080,200
$2.16+0.04+1.9%$2.17$2.18$2.09106,300
$2.12-0.02-0.9%$2.15$2.15$2.09184,700
$2.14+0.04+1.9%$2.09$2.17$2.0870,100
$2.10-0.01-0.5%$2.12$2.15$2.08109,900
$2.11-0.02-0.9%$2.14$2.17$2.1083,700
$2.13-0.01-0.5%$2.25$2.25$2.1272,200
$2.14-0.09-4.0%$2.23$2.24$2.1465,500
$2.23-0.06-2.6%$2.29$2.29$2.1766,200
$2.29+0.07+3.2%$2.21$2.32$2.2148,300
$2.22-0.04-1.8%$2.29$2.46$2.20716,000
$2.26+0.12+5.6%$2.24$2.31$2.20397,500
$2.14+0.02+0.9%$2.12$2.15$2.07224,700
$2.12+0.02+1.0%$2.09$2.14$2.05159,500
$2.10-0.04-1.9%$2.12$2.19$2.08186,300
$2.140.000.0%$2.15$2.20$2.07159,200
$2.14+0.04+1.9%$2.19$2.19$2.1049,000
$2.10-0.03-1.4%$2.09$2.14$2.0777,700
$2.13+0.01+0.5%$2.10$2.14$2.07117,300
$2.12-0.04-1.9%$2.16$2.16$2.1266,100
$2.16+0.01+0.5%$2.10$2.18$2.1082,300
$2.15-0.05-2.3%$2.20$2.20$2.1422,200
$2.20+0.02+0.9%$2.18$2.22$2.1894,443
$2.18-0.02-0.9%$2.23$2.23$2.1386,601
$2.20+0.06+2.8%$2.15$2.23$2.1575,900
$2.14-0.06-2.7%$2.19$2.24$2.1054,700

Splits

3 splits since 2015 · NASDAQ:GRCE · every price before a split is adjusted for it

DayRatioWhat
1-for-6Consolidation
1-for-8Consolidation
1-for-10Consolidation
Ticker
NASDAQ:GRCE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Grace Therapeutics, Inc. news

Grace Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
12 in the last 12 months · 31 in all · newest Nov 12, 2026 · oldest 2024
Calls
6 calls with a replay · 6 with a transcript · latest Feb 14, 2023
Decks
10 decks · latest Jul 28, 2026

Where Grace Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:GRCE · Home listing · This pageNASDAQUnited StatesUSD
BOATS:GRCEBOATSUnited StatesUSD
Lang & Schwarz:A40LELLang & SchwarzGermanyEUR
Frankfurt:L8SFrankfurtGermanyEUR

Cash and shares

Mar 31, 2026 · Grace Therapeutics — Investor Presentation (July 2026)

Shares outstanding
16,024,026
Fully diluted
23,033,731

The slide these figures come from

Valuation

Price/book 0.7× against a median of 2.4×: 3rd lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$14.66M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.77

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Grace Therapeutics, Inc. · NASDAQ:GRCEUS$35.97MUS$14.66Mn/an/an/a0.7×n/a0.0×0.77
KoBioLabs, Inc. · KRX:348150US$38.23MUS$6.96Mn/a0.1×n/a1.8×−6.4%0.2×n/a
Sprint Bioscience AB · OMXSTO:SPRINTUS$38.02MUS$28.89M5.1×2.1×3.7×4.3×54.4%0.0×n/a
Theralase Technologies Inc. · TSXV:TLTUS$37.89MUS$34.22Mn/a61.1×n/a7.9×−472.5%0.0×0.75
Connect Biopharma Holdings Limited · NASDAQ:CNTBUS$37.15MUS$18.16Mn/a4.9×n/a3.1×n/a0.0×0.93
Coiled Therapeutics PLC · LSE:COILUS$37.13MUS$30.46Mn/an/an/a0.6×n/a0.0×n/a
TaiRx, Inc. · TPEX:6580US$37.07MUS$28.61Mn/a33.8×n/a3.3×−793.3%0.0×n/a
Pliant Therapeutics, Inc. · NASDAQ:PLRXUS$36.89M−US$104.2Mn/an/an/a0.3×n/a0.0×1.06
Arovella Therapeutics Limited · ASX:ALAUS$36.01MUS$26.51Mn/an/an/a3.8×n/a0.0×n/a
Cantargia AB · OMXSTO:CANTAUS$35.59MUS$13.85M2.2×0.5×0.9×1.4×52.8%0.0×n/a
Cue Biopharma, Inc. · NASDAQ:CUEUS$34.69M−US$23.25Mn/a−0.7×n/a0.9×−580.0%0.0×2.35
Median of the othersUS$37.10MUS$22.33M3.6×2.1×2.3×2.4×−239.4%0.0×1.00

Forecasts

2 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
5.85 USD · Analysts' mean
EPS, year to Mar 2027
-0.76 · 1 analyst

Team and board

Officers

OfficerRole
Prashant KohliChief Executive Officer and Director
Amresh KumarVice President Program Management
R. Loch MacdonaldChief Medical Officer
Robert J. DelAversanoPrincipal Financial Officer and Principal Accounting Officer

Board

DirectorRole
Vimal KavuruChair of the Board
Brian DavisDirector
Edward NeugeborenDirector
George KottayilDirector
Prashant KohliChief Executive Officer and Director

Events

Calls

CallWhenStatus
Acasti Pharma, Inc. (ACST) Q3 2023 Earnings CallTue, Feb 14, 2023 · 1:00 PM ETReplay
Acasti Pharma, Inc. (ACST) Q2 2023 Earnings CallMon, Nov 14, 2022 · 1:00 PM ETReplay
Acasti Pharma, Inc. (ACST) Q1 2023 Earnings CallThu, Aug 11, 2022 · 1:00 PM ETReplay
Acasti Pharma, Inc. (ACST) Q4 2022 Earnings CallTue, Jun 21, 2022 · 1:00 PM ETReplay
Acasti Pharma, Inc. (ACST) Q3 2022 Earnings CallMon, Feb 14, 2022 · 1:00 PM ETReplay
Acasti Pharma, Inc. (ACST) Q2 2022 Earnings CallWed, Nov 10, 2021 · 1:00 PM ETReplay

Results days

QuarterResultsShare move
Q2 2027Nov 12, 2026 · Before open−2.4%
Q1 2027Aug 13, 2026 · Before open−1.4%
Q4 2026Jun 18, 2026 · Before open+7.2%
Q3 2026Feb 12, 2026 · Before open−1.7%
Q2 2026Nov 13, 2025 · Before open+2.3%
Q1 2026Aug 12, 2025 · Before open+3.5%
Q4 2025Jun 23, 20250.0%
Q3 2025Feb 17, 2025−0.9%
Q2 2025Nov 13, 2024 · Before open−4.4%
Q1 2025Aug 9, 2024 · Before open−3.3%
All 20 quarters
QuarterResultsShare move
Q4 2024Jun 21, 2024+1.6%
Q3 2024Feb 12, 2024 · Before open+6.5%
Q2 2024Nov 13, 2023 · Before open−3.1%
Q1 2024Aug 11, 2023 · Before open0.0%
Q4 2023Jun 23, 2023−5.3%
Q3 2023Feb 14, 2023 · Before open+3.1%
Q2 2023Nov 14, 20220.0%
Q1 2023Aug 11, 2022+7.9%
Q4 2022Jun 21, 2022 · Before open0.0%
Q3 2022Feb 14, 2022 · Before open+7.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck31 slidesJul 28, 2026
Investor Presentation (April 2026)Investor deck32 slidesApr 27, 2026
Investor Presentation (2026)Investor deck29 slides2026
Investor Presentation (November 2025)Investor deck31 slidesNov 13, 2025
Investor Presentation (March 2025)Investor deck30 slidesMar 3, 2025
Investor Presentation (February 2025)Investor deck35 slidesFeb 10, 2025
Acasti Pharma — Investor Presentation (April 2024)Investor deck18 slidesApr 1, 2024
Acasti Pharma — Merger or Acquisition (May 2021)Merger or acquisition21 slidesMay 7, 2021
Acasti Pharma — IPO Roadshow (November 2017)IPO roadshow46 slidesNov 24, 2017
Acasti Pharma — Shareholder Meeting (June 2016)Shareholder meeting4 slidesJun 14, 2016

Open Decks

Financings

RaiseDate
Private placement of private placement financing
Update: about US$10M · US$2.1 a share · Craig-Hallum
Dealers: Craig-Hallum (lead)
Use of proceeds: Support the manufacturing and regulatory work needed to advance GTx-104
Aug 13, 2026
Warrant exercise of common stock on exercise of common warrants
Closed: US$4M raised · US$3.003 a share
Oct 23, 2025
Private placement of securities with accompanying warrants
Closed: US$15M raised
Buyers: Nantahala Capital (co-led the financing); ADAR1 Partners, LP (co-led the financing); Stonepine Capital Management
Use of proceeds: Pre-commercial planning, commercial team build out and product launch of GTx-104 if approved
Feb 13, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue0000100.0M196.0K
Cost of revenue7.00K7.00K11.0K124.0K076.0K3.12M2.68M2.57M
Gross profit-7.00K-7.00K-11.0K-124.0K0189.4K-3.12M-2.68M-2.57M
Research and development2.40M9.51M4.68M9.97M5.56M4.17M16.0M29.4M12.1M7.18M
Selling, general and administrative8.66M10.2M9.02M10.9M12.1M8.70M11.6M3.80M3.12M
Operating income-11.1M-16.7M-12.9M-52.2M-15.6M-16.4M-24.4M-34.4M-15.3M-10.5M
Depreciation and amortization7.00K7.00K11.0K124.0K0143.0K410.0K384.0K2.07M2.57M
EBITDA-11.1M-16.7M-12.8M-52.0M-15.6M-16.3M-24.0M-34.0M-13.2M-7.95M
Interest expense331.6K414.2K1.05M371.6K54.4K
Income before tax-9.49M-12.8M-14.7M-52.0M-10.5M-19.7M-25.5M-39.4M-16.7M-10.7M
Income tax-1.70M-3.20M-1.83M-9.54M-648.0K000-121.1K
Net income-7.79M-9.57M-12.9M-42.4M-9.82M-19.7M-25.5M-39.4M-16.7M-10.6M
Earnings per share, basic-0.47-0.79-1.35-5.71-0.27-1.33-0.30-0.73-45.71-45.67
Earnings per share, diluted-0.47-0.79-1.35-5.71-0.27-1.33-0.30-0.73

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents17.0M22.1M23.0M27.9M30.3M50.9M14.2M16.9M6.37M
Short-term investments015.0K13.3M9.79M9.79M8.89M
Receivables20.0K126.0K722.0K802.0K548.0K530.0K546.0K1.19M759.3K206.2K
Inventory1
Current assets17.4M22.7M24.0M29.3M45.3M62.4M18.5M28.0M7.35M10.2M
Property, plant and equipment8.00K15.0K24.0K104.0K20.9M1.91M2.11M
Goodwill8.14M8.14M8.14M8.14M13.0M0
Total assets66.7M72.0M73.3M79.1M128.6M62.5M22.9M36.9M17.8M25.5M
Accounts payable702.0K601.0K1.01M1.24M3.16M144.5K2.42M3.05M2.65M
Current liabilities2.15M1.93M1.68M3.41M3.26M1.58M7.39M13.7M5.19M2.14M
Total debt485.0K295.0K108.0K207.8K1.36M1.25M1.41M
Total liabilities2.76M5.38M11.6M11.2M20.4M6.80M9.86M25.9M11.4M3.76M
Shareholders' equity63.9M66.6M61.7M68.0M108.3M55.7M13.0M11.0M6.37M21.7M
Shares outstanding16.0M13.7M9.40M7.44M44.3M44.6M44.4M208.4M364.3K231.1K

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-8.87M-14.9M-12.3M-15.9M-17.2M-14.3M-23.0M-24.8M-9.69M-6.94M
Capital spending00-22.0K-17.0K0-86.7K-450.9K-534.0K-352.3K-2.57M
Free cash flow-8.87M-14.9M-12.4M-15.9M-17.2M-18.1M-32.9M-25.3M-10.0M-9.51M
Cash from investing00104.0K13.2M-3.52M-9.86M8.14M-9.44M-318.3K6.85M
Cash from financing3.71M14.0M7.36M304.0K059.5M13.2M45.7M8.83M7.00M
Share buybacks-31.0K
Change in cash-5.16M-872.0K-4.87M-2.46M-20.6M36.7M-2.63M10.4M-1.20M-2.98M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 1, 2026Insider tradeSEC
4/A · Change in ownership, amendedOct 1, 2026Insider tradeSEC
4 · Change in ownershipSep 23, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
8-K · Current reportSep 18, 2026Meeting outcomeSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveSep 1, 2026Other filingsSEC
S-3 · Registration statementAug 24, 2026Offer documentSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 13, 2026ResultsSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
DAug 10, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
8-K · Current reportAug 6, 2026Material contractSEC
DEFA14A · Additional proxy materialJul 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementJul 28, 2026Meeting noticeSEC
8-K · Current reportJul 28, 2026Current reportSEC
8-K · Current reportJun 18, 2026Current reportSEC
8-K · Current reportJun 18, 2026ResultsSEC
10-K · Annual reportJun 18, 2026Annual reportSEC
8-K · Current reportJun 5, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 27, 2026Big-stake noticeSEC
8-K · Current reportApr 27, 2026Current reportSEC
8-K · Current reportApr 23, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
8-K · Current reportFeb 12, 2026ResultsSEC
10-Q · Quarterly reportFeb 12, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 28, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026Management or board changeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
10-Q/A · Quarterly report, amendedNov 17, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportOct 23, 2025Current reportSEC
8-K · Current reportSep 18, 2025Current reportSEC
8-K · Current reportSep 12, 2025Meeting outcomeSEC
8-K · Current reportAug 27, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 12, 2025ResultsSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
DEFA14A · Additional proxy materialJul 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementJul 28, 2025Meeting noticeSEC
8-K · Current reportJun 25, 2025Current reportSEC
8-K · Current reportJun 23, 2025ResultsSEC
10-K · Annual reportJun 23, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 8, 2025Big-stake noticeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
8-K · Current reportApr 9, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveMar 14, 2025Other filingsSEC
CORRESP · Letter to the SECMar 12, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 11, 2025Other filingsSEC
S-3 · Registration statementMar 10, 2025Offer documentSEC
8-K · Current reportMar 3, 2025Current reportSEC
DFeb 25, 2025Other filingsSEC
10-Q/A · Quarterly report, amendedFeb 18, 2025Quarterly reportSEC
8-K · Current reportFeb 13, 2025ResultsSEC
10-Q · Quarterly reportFeb 13, 2025Quarterly reportSEC
8-K · Current reportFeb 10, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 29, 2025Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
8-K · Current reportNov 13, 2024ResultsSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportOct 28, 2024Current reportSEC
8-K · Current reportOct 25, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveOct 16, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveOct 16, 2024Other filingsSEC
S-8 · Registration statement for employee plansOct 8, 2024Offer documentSEC
S-8 POSOct 8, 2024Offer documentSEC
S-8 POSOct 8, 2024Offer documentSEC
S-8 POSOct 8, 2024Offer documentSEC
POS AM · Amendment to an effective registrationOct 8, 2024Offer documentSEC
POS AM · Amendment to an effective registrationOct 8, 2024Offer documentSEC
8-K · Current reportOct 7, 2024Material contractSEC
8-K · Current reportSep 30, 2024Management or board changeSEC
8-K · Current reportSep 25, 2024Current reportSEC
DEFA14A · Additional proxy materialSep 6, 2024Meeting noticeSEC
8-K · Current reportAug 16, 2024Management or board changeSEC
8-K · Current reportAug 9, 2024ResultsSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialAug 7, 2024Meeting noticeSEC
424B3 · ProspectusAug 7, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 5, 2024Other filingsSEC
CORRESP · Letter to the SECJul 31, 2024Other filingsSEC
S-4/A · Registration statement, amendedJul 31, 2024Offer documentSEC
3/A · Initial statement of ownership, amendedJul 11, 2024Insider tradeSEC
SC 13G · Big-stake noticeJul 10, 2024Big-stake noticeSEC
3 · Initial statement of ownershipJul 9, 2024Insider tradeSEC
UPLOAD · Letter from the SECJul 3, 2024Other filingsSEC
S-4 · Registration statementJun 27, 2024Offer documentSEC
8-K · Current reportJun 27, 2024Current reportSEC
8-K · Current reportJun 21, 2024ResultsSEC
10-K · Annual reportJun 21, 2024Annual reportSEC
4/A · Change in ownership, amendedMay 10, 2024Insider tradeSEC
4/A · Change in ownership, amendedMay 10, 2024Insider tradeSEC
4 · Change in ownershipMay 8, 2024Insider tradeSEC
4 · Change in ownershipMay 8, 2024Insider tradeSEC
4 · Change in ownershipMay 8, 2024Insider tradeSEC
4 · Change in ownershipMay 8, 2024Insider tradeSEC
4 · Change in ownershipMay 8, 2024Insider tradeSEC
SC 13G · Big-stake noticeApr 9, 2024Big-stake noticeSEC
8-K · Current reportApr 1, 2024Current reportSEC
SC 13G · Big-stake noticeFeb 13, 2024Big-stake noticeSEC
8-K · Current reportFeb 12, 2024ResultsSEC
10-Q · Quarterly reportFeb 12, 2024Quarterly reportSEC
3 · Initial statement of ownershipJan 8, 2024Insider tradeSEC
8-K · Current reportJan 8, 2024Management or board changeSEC
4 · Change in ownershipDec 20, 2023Insider tradeSEC
4 · Change in ownershipDec 20, 2023Insider tradeSEC
4 · Change in ownershipDec 20, 2023Insider tradeSEC
4 · Change in ownershipDec 20, 2023Insider tradeSEC
4 · Change in ownershipDec 20, 2023Insider tradeSEC
8-K · Current reportDec 15, 2023Current reportSEC
8-K · Current reportNov 13, 2023ResultsSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportOct 23, 2023Material contractSEC
3 · Initial statement of ownershipOct 20, 2023Insider tradeSEC
3 · Initial statement of ownershipOct 20, 2023Insider tradeSEC
3 · Initial statement of ownershipOct 20, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveOct 17, 2023Other filingsSEC
424B3 · ProspectusOct 16, 2023Offer documentSEC
CORRESP · Letter to the SECOct 12, 2023Other filingsSEC
UPLOAD · Letter from the SECOct 12, 2023Other filingsSEC
8-K · Current reportOct 11, 2023Meeting outcomeSEC
DOct 10, 2023Other filingsSEC
S-3 · Registration statementOct 6, 2023Offer documentSEC
4 · Change in ownershipSep 27, 2023Insider tradeSEC
8-K · Current reportSep 26, 2023Material contractSEC
4 · Change in ownershipSep 5, 2023Insider tradeSEC
S-8 · Registration statement for employee plansAug 25, 2023Offer documentSEC
DEFA14A · Additional proxy materialAug 25, 2023Meeting noticeSEC
DEF 14A · Proxy statementAug 25, 2023Meeting noticeSEC
8-K · Current reportAug 11, 2023ResultsSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
8-K · Current reportJul 24, 2023Current reportSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
8-K · Current reportJul 7, 2023Current reportSEC
8-K · Current reportJul 5, 2023Current reportSEC
8-K · Current reportJun 23, 2023ResultsSEC
10-K · Annual reportJun 23, 2023Annual reportSEC
3 · Initial statement of ownershipMay 26, 2023Insider tradeSEC
3 · Initial statement of ownershipMay 18, 2023Insider tradeSEC
3 · Initial statement of ownershipMay 18, 2023Insider tradeSEC
8-K · Current reportMay 11, 2023Management or board changeSEC
8-K · Current reportApr 5, 2023Management or board changeSEC
8-K · Current reportMar 31, 2023Management or board changeSEC
8-K · Current reportMar 13, 2023Current reportSEC
8-K · Current reportFeb 22, 2023Current reportSEC
8-K · Current reportFeb 14, 2023ResultsSEC
10-Q · Quarterly reportFeb 14, 2023Quarterly reportSEC
8-K · Current reportJan 25, 2023Current reportSEC
8-K · Current reportDec 28, 2022Current reportSEC
8-K · Current reportDec 22, 2022Current reportSEC
8-K · Current reportNov 14, 2022ResultsSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
4 · Change in ownershipSep 30, 2022Insider tradeSEC
4 · Change in ownershipSep 30, 2022Insider tradeSEC

This page holds 200 of 599 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Grace Therapeutics, Inc.’s releases · as of Nov 11, 2026

Common shares
21,035,930
Fully diluted
21,035,930

Fully diluted

LineSharesAs of
Common shares21,035,930Nov 11, 2026

Share count over time

CountShares
Nov 11, 202621,035,930
Sep 30, 202621,035,930

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Opaleye Management Inc.2.8M13.3%US$6.02MSep 30, 2026
Cerity Partners LLC849K4.0%US$1.83MSep 30, 2026
Eversept Partners, LP770K3.7%US$1.66MSep 30, 2026
Bank of America495K2.4%US$1.06MSep 30, 2026
Nantahala Capital Management, LLC476K2.3%US$1.02MSep 30, 2026
Rosalind Advisors, Inc.476K2.3%US$1.02MSep 30, 2026
ADAR1 Capital Management, LLC476K2.3%US$1.02MSep 30, 2026
Vanguard409K1.9%US$880KSep 30, 2026
Renaissance Technologies186K0.88%US$400KSep 30, 2026
Two Sigma127K0.60%US$273KSep 30, 2026
All 37 holders
HolderSharesOf the companyValueAs of
Cantor Fitzgerald, L. P.100K0.48%US$215KSep 30, 2026
Citadel66,6960.32%US$143KSep 30, 2026
Jane Street62,7250.30%US$135KSep 30, 2026
Susquehanna55,3190.26%US$119KSep 30, 2026
BlackRock35,9150.17%US$77,217Sep 30, 2026
XTX Topco Ltd35,7720.17%US$76,910Sep 30, 2026
Citigroup Inc35,4810.17%US$76,284Sep 30, 2026
Rangeley Capital, LLC25,2080.12%US$54,197Sep 30, 2026
Kestra Private Wealth Services, LLC23,0000.11%US$49,450Sep 30, 2026
Morgan Stanley22,7630.11%US$48,940Sep 30, 2026
Johnson Dunn Capital Advisors Inc19,5000.09%US$41,925Sep 30, 2026
BNP Paribas15,9000.08%US$34,185Sep 30, 2026
Axq Capital, LP12,2210.06%US$26,275Sep 30, 2026
Oppenheimer & Co Inc10,0000.05%US$21,500Sep 30, 2026
National Bank Of Canada2,6800.01%US$5,708Sep 30, 2026
UBS2,2890.01%US$4,921Sep 30, 2026
Tower Research Capital LLC (TRC)2,2580.01%US$4,855Sep 30, 2026
RBC898<0.01%US$2,000Sep 30, 2026
Nuveen863<0.01%US$1,821Sep 30, 2026
Arax Advisory Partners250<0.01%US$538Sep 30, 2026
Activest Wealth Management104<0.01%US$224Sep 30, 2026
SBI Securities Co., Ltd.77<0.01%US$166Sep 30, 2026
JPMorgan58<0.01%US$122Sep 30, 2026
Harbour Investments, Inc.37<0.01%US$80Sep 30, 2026
Osaic Holdings, Inc.31<0.01%US$65Sep 30, 2026
Lanark Financial, Inc.2<0.01%US$4Sep 30, 2026
Caitong International Asset Management Co., Ltd1<0.01%US$2Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund400K1.9%US$909KJun 30, 2026
iShares Micro-Cap ETF35,1880.17%US$79,877Jun 30, 2026
Tiff Multi-Asset Fund16,2390.08%US$36,863Jun 30, 2026
Vanguard Balanced Index Fund11,3640.05%US$25,796Jun 30, 2026
Fidelity Nasdaq Composite Index Fund5,5710.03%US$14,317May 31, 2026
1290 VT Micro Cap Portfolio2,3470.01%US$5,328Jun 30, 2026
Total Stock Market Index Trust778<0.01%US$1,766Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Opaleye Management Inc.
10% owner
Buy2,974USD 1.73US$5,131Nov 18, 2026
Opaleye Management Inc.
10% owner
Buy29,207USD 1.72US$50,292Nov 17, 2026
Opaleye Management Inc.
10% owner
Buy15,879USD 1.76US$28,012Nov 16, 2026
Opaleye Management Inc.
10% owner
Buy3,087USD 1.77US$5,478Nov 5, 2026
Opaleye Management Inc.
10% owner
Buy5,027USD 1.80US$9,060Nov 4, 2026
Opaleye Management Inc.
10% owner
Buy10,328USD 1.79US$18,481Nov 3, 2026
Opaleye Management Inc.
10% owner
Buy66,411USD 1.77US$117KOct 26, 2026
Opaleye Management Inc.
10% owner
Buy21,390USD 1.93US$41,193Oct 22, 2026
Opaleye Management Inc.
10% owner
Buy4,256USD 1.88US$8,001Oct 19, 2026
Opaleye Management Inc.
10% owner
Buy36,347USD 1.89US$68,758Oct 16, 2026
All 27 trades
TradeTradeSharesPriceValueDate
Opaleye Management Inc.
10% owner
Buy23,485USD 1.95US$45,685Oct 15, 2026
Opaleye Management Inc.
10% owner
Buy11,233USD 1.93US$21,735Oct 14, 2026
Opaleye Management Inc.
10% owner
Buy7,215USD 2.02US$14,574Oct 12, 2026
Opaleye Management Inc.
10% owner
Buy5,340USD 2.04US$10,918Oct 9, 2026
Opaleye Management Inc.
10% owner
Buy2,077USD 2.02US$4,190Oct 8, 2026
Opaleye Management Inc.
10% owner
Buy1,694USD 2.06US$3,490Oct 5, 2026
Opaleye Management Inc.
10% owner
Buy20,000USD 2.07US$41,368Oct 2, 2026
Opaleye Management Inc.
10% owner
Buy38,796USD 2.04US$78,961Oct 1, 2026
Opaleye Management Inc.
10% owner
Buy7,849USD 2.09US$16,404Sep 29, 2026
Opaleye Management Inc.
10% owner
Buy5,318USD 2.10US$11,168Sep 23, 2026
Opaleye Management Inc.
10% owner
Buy5,318USD 2.10US$11,168Sep 23, 2026
Opaleye Management Inc.
10% owner
Buy9,771USD 2.10US$20,519Sep 21, 2026
Opaleye Management Inc.
10% owner
Buy9,771USD 2.10US$20,519Sep 21, 2026
Kohli Prashant
Director, Officer: Chief Executive Officer
Buy100,000USD 2.14US$214KSep 9, 2026
Opaleye Management Inc.
10% owner
Buy5,836USD 2.09US$12,197Sep 9, 2026
Opaleye Management Inc.
10% owner
Buy9,393USD 2.10US$19,725Sep 8, 2026
Opaleye Management Inc.
10% owner
Buy11,608USD 2.09US$24,261Aug 14, 2026

Big stakes

StakeStakeSharesDateFiling
Opaleye Management Inc.13.07%2.75MAug 5, 2026Schedule 13G
ADAR1 Capital Management, LLC9.90%2.28MSep 30, 2026Schedule 13G
Nantahala Capital Management, LLC7.45%1.65MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Brian Davis
Other companies: Verrica Pharmaceuticals Inc. (Chief Financial Officer · Oct 18, 2019 – Jun 4, 2021 · Past); Strongbridge Biopharma plc (Chief Financial Officer · Jan 1, 2018 – Feb 20, 2019 · Past); Tengion Inc (Chf. Fin. Offr, VP Fin. · Aug 1, 2010 – Mar 4, 2013 · Past)
Director · Since at least Oct 10, 2023
John Canan
Other companies: Terex Corporation (Director · Since at least Feb 2, 2026); Rev Group Inc (Director · Since at least Dec 11, 2020)
Director · Nov 12, 2021 – Sep 28, 2022 · Past
Brian J Groch
Other companies: Veru Inc. (Chief Commercial Officer · Jan 1, 2017 – Dec 14, 2017 · Past)
CHIEF COMMERCIAL OFFICER · Apr 1, 2020 – Apr 1, 2020 · Past
Donald Olds
Other companies: Retension Pharmaceuticals, Inc. (Director · Since at least Oct 13, 2026)
Director · Apr 1, 2020 – Aug 31, 2023 · Past
Edward Neugeboren
Other companies: Matinas BioPharma Holdings, Inc. (Board Member · Since at least Mar 11, 2025)
Director · Since at least Oct 10, 2023
Robert J. DelAversano
Other companies: U.S. Gold Corp. (See Remarks · Dec 22, 2017 – Apr 10, 2018 · Past)
Principal Financial Officer and Principal Accounting Officer · Since at least Jan 5, 2024
Amresh KumarVice President Program Management · Since at least May 8, 2023
Brian D FordCHIEF FINANCIAL OFFICER · Sep 14, 2020 – Jun 22, 2022 · Past
Carrie D'AndreaVP Clinical Operations · May 8, 2023 – Apr 14, 2025 · Past
George KottayilDirector · Since at least Nov 10, 2021
All 18 people
PersonSeat
Janelle D'AlvisePRESIDENT & CEO, Director · Apr 1, 2020 – Jun 22, 2022 · Past
Jean-Francois BoilyVICE-PRESIDENT, FINANCE · Apr 1, 2020 – Apr 1, 2020 · Past
Pierre LemieuxCOO, Canada & CSO · Apr 1, 2020 – Jun 22, 2022 · Past
Prashant KohliChief Executive Officer and Director · Since at least Sep 9, 2022
R. Loch MacdonaldChief Medical Officer · Since at least May 8, 2023
Roderick Noel CarterDirector · Apr 1, 2020 – Nov 12, 2021 · Past
Vimal KavuruChair of the Board · Since at least Aug 27, 2021
William A HaseltineDirector · Aug 27, 2021 – Nov 12, 2021 · Past

Open People

Log in to ask 6ix AI your own questions about Grace Therapeutics, Inc.